博雅生物(300294) - 2021年11月23日投资者关系活动记录表

Management Changes - The management team is actively coordinating with China Resources Pharmaceutical for strategic planning and governance adjustments [1] - The board of directors is being re-elected, with the number of directors increasing from 7 to 9, allowing China Resources to appoint 6 out of 9 directors [1] Financial Performance - The company has launched PCC products this year, which are expected to positively impact revenue and profit from ton plasma sales [3] - The product mix is balanced, with albumin, immunoglobulin, and factor products each accounting for approximately one-third of total sales [3] Research and Development - The company is focusing on blood product R&D, with plans to introduce 3-4 new products during the 14th Five-Year Plan period [4] - Key products in development include factor VIII, which is expected to be approved for production next year, and high-concentration immunoglobulin, anticipated to enter the market in 2024 [3][4] Capacity Expansion - Preparatory work for new capacity construction is nearly complete, with formal construction expected to start after the new board's review [3] - The company is actively expanding plasma stations, particularly after China Resources became the largest shareholder [3][4] Market Strategy - The company aims to enhance its focus on blood products, aligning with China Resources' strategic requirements [4] - The company plans to double its plasma volume and improve product marketing and academic promotion efforts during the 14th Five-Year Plan [4] Goodwill and Risk Management - The company's goodwill, primarily from acquisitions, totals 660 million yuan, with no signs of impairment currently [4] - The impact of centralized procurement on blood products is expected to be minimal due to overall industry supply and demand dynamics [4]